205 related articles for article (PubMed ID: 19859790)
1. c-Jun-NH2 terminal kinase (JNK)-mediates AP-1 activation by thioredoxin: phosphorylation of cJun, JunB, and Fra-1.
Das KC; Muniyappa H
Mol Cell Biochem; 2010 Apr; 337(1-2):53-63. PubMed ID: 19859790
[TBL] [Abstract][Full Text] [Related]
2. Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death.
Brandt B; Abou-Eladab EF; Tiedge M; Walzel H
Cell Death Dis; 2010; 1(2):e23. PubMed ID: 21364631
[TBL] [Abstract][Full Text] [Related]
3. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.
Muniyappa H; Das KC
Cell Signal; 2008 Apr; 20(4):675-83. PubMed ID: 18222647
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p38 MAP kinase increases okadaic acid mediated AP-1 expression and DNA binding but has no effect on TRE dependent transcription.
Rosenberger SF; Gupta A; Bowden GT
Oncogene; 1999 Jun; 18(24):3626-32. PubMed ID: 10380884
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin Activates MKK4-NFκB Pathway in a Redox-dependent Manner to Control Manganese Superoxide Dismutase Gene Expression in Endothelial Cells.
Kundumani-Sridharan V; Subramani J; Das KC
J Biol Chem; 2015 Jul; 290(28):17505-19. PubMed ID: 26028649
[TBL] [Abstract][Full Text] [Related]
6. AP-1 activation and altered AP-1 composition in association with increased phosphorylation and expression of specific Jun and Fos family proteins induced by vinblastine in KB-3 cells.
Berry A; Goodwin M; Moran CL; Chambers TC
Biochem Pharmacol; 2001 Sep; 62(5):581-91. PubMed ID: 11585055
[TBL] [Abstract][Full Text] [Related]
7. The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun.
Humar M; Loop T; Schmidt R; Hoetzel A; Roesslein M; Andriopoulos N; Pahl HL; Geiger KK; Pannen BH
Int J Biochem Cell Biol; 2007; 39(12):2278-88. PubMed ID: 17689131
[TBL] [Abstract][Full Text] [Related]
8. c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IkappaB: role of thioredoxin in NF-kappaB activation.
Das KC
J Biol Chem; 2001 Feb; 276(7):4662-70. PubMed ID: 11063742
[TBL] [Abstract][Full Text] [Related]
9. Type II cGMP-dependent protein kinase inhibits ERK/JNK-mediated activation of transcription factors in gastric cancer cells.
Sang J; Chen Y; Jiang L; Tao Y; Wu Y; Wang Y; Li Y; Lan T; Shao G
Mol Med Rep; 2012 Nov; 6(5):1190-4. PubMed ID: 22940826
[TBL] [Abstract][Full Text] [Related]
10. The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1.
Chalmers CJ; Gilley R; March HN; Balmanno K; Cook SJ
Cell Signal; 2007 Apr; 19(4):695-704. PubMed ID: 17052890
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Delgado M; Ganea D
J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
[TBL] [Abstract][Full Text] [Related]
12. The role of JNK and p38 MAPK activities in UVA-induced signaling pathways leading to AP-1 activation and c-Fos expression.
Silvers AL; Bachelor MA; Bowden GT
Neoplasia; 2003; 5(4):319-29. PubMed ID: 14511403
[TBL] [Abstract][Full Text] [Related]
13. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
[TBL] [Abstract][Full Text] [Related]
14. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
Hammaker DR; Boyle DL; Chabaud-Riou M; Firestein GS
J Immunol; 2004 Feb; 172(3):1612-8. PubMed ID: 14734742
[TBL] [Abstract][Full Text] [Related]
15. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.
Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM
Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747
[TBL] [Abstract][Full Text] [Related]
16. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
Suzukawa K; Colburn NH
Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
[TBL] [Abstract][Full Text] [Related]
17. RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells.
Yu W; Simmons-Menchaca M; You H; Brown P; Birrer MJ; Sanders BG; Kline K
Mol Carcinog; 1998 Aug; 22(4):247-57. PubMed ID: 9726817
[TBL] [Abstract][Full Text] [Related]
18. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
[TBL] [Abstract][Full Text] [Related]
19. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.
Diefenbacher M; Sekula S; Heilbock C; Maier JV; Litfin M; van Dam H; Castellazzi M; Herrlich P; Kassel O
Mol Endocrinol; 2008 Aug; 22(8):1767-80. PubMed ID: 18535250
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun pathway.
Hoffmann E; Ashouri J; Wolter S; Doerrie A; Dittrich-Breiholz O; Schneider H; Wagner EF; Troppmair J; Mackman N; Kracht M
J Biol Chem; 2008 May; 283(18):12120-8. PubMed ID: 18281687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
